PwC predicts 'flurry' of $5B to $15B biotech deals in 2023

PwC’s pharma industry trends analysis is here — and the audit company is predicting several negatives amid modest expectations for M&A, covering everything from high inflation and rising capital costs to increased FTC scrutiny, just to name a few.

The report recommends leaders focus on four key areas: digitizing the value chain, “getting fit for growth” by rethinking where they allocate funds, finding ways to adapt to pressure on drug pricing and “winning” in M&A.